The PPARy2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes

Emanuela Lapice1*, Antonella Monticelli2,3, Sergio Cocozza2, Michele Pinelli2, Sara Cocozza1, Dario Bruzzese4, Gabriele Riccardi1 and Olga Vaccaro1

Abstract

Objective: Cross-sectional studies suggest the association between diabetic nephropathy and the PPARy2 Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 (PPARγ2). Prospective data are limited to microalbuminuria and no information on renal function is available to date. The present study evaluates the association between the Pro12Ala polymorphism of PPARγ2 and the progression of albuminuria and decay in glomerular filtration rate (GFR) in type 2 diabetes.

Patients and measurements: We studied 256 patients with an average 5-year follow-up. Among others, urinary albumin excretion rate (UAER) was measured on spot sample, GFR was estimated with the CKD-EPI Equation.

Results: Baseline UAER and GFR were similar for carriers or non-carriers of the polymorphism. At follow-up no significant changes from baseline were observed for UAER or eGFR in carriers of the Pro12Ala polymorphism whereas a significant increase in UAER [17 (11.3-37.9) versus 24.5 (13.8-49.9) μg/mg, p < 0.006] and a significant reduction in the eGFR (82.8 ± 14.5 versus 80.3 ± 17.3 ml/min/1.73 m², p = 0.02), were observed in non carriers of the Pro12Ala polymorphism. Progression of nephropathy - defined according to a combined end point of UAER and eGFR - i.e. doubling of baseline UAER to at least 100 μg/mg, or new onset microalbuminuria, or progression from micro to macroalbuminuria, or 25% reduction of eGFR, or annualized eGFR decline >3 ml/min/year - was significantly less frequent in Ala carriers than non carriers (11.4% vs 35.8%; p < 0.01); HR adjusted for baseline age, AER, eGFR, HbA1c, diabetes duration and blood pressure was 0.32 (0.12-0.80).

Conclusions: This study found that among patients with type 2 diabetes, the PPARy2 Pro12Ala polymorphism is protective against progression of nephropathy and decay of renal function independent of major confounders.

Keywords: Nephropathy, PPAR-gamma polymorphism, Type 2 diabetes

Introduction

The etiology of diabetic nephropathy is not fully understood; while environmental factors certainly play a major role, the familial aggregation of the disease and the disproportionate prevalence among specific ethnic groups, suggests that genetic factors may influence the risk of the disease [1]. Among others the peroxisome proliferator-activated receptor (PPARy) gene has been associated with the risk of diabetic nephropathy [2]. In particular the Ala12 variant of the PPAR γ2 isoform has been consistently associated with less insulin resistance and increased resistance to oxidative stress [3,4]. Both conditions have been suggested to contribute to the development and progression of diabetic nephropathy [5-7]. Moreover animal and human studies suggest that the thiazolidinediones, which act as PPARγ2 agonists, may reduce urinary albumin excretion rate (UAER) and may prevent the development of renal injury [8], thus further supporting a role for PPARγ2 in the phenotype diabetic nephropathy. So far genetic association studies investigating the relation of the PPARγ2 Pro12Ala polymorphism with diabetic nephropathy have provided not entirely consistent results [9-17].
Differences in the methods for the assessment of UAER (i.e. timed urine collection versus a spot urine albumin-to-creatinine ratio, single or repeated measures of albuminuria) and different ethnic composition and genetic susceptibility to nephropathy of the populations studied, may partly explain discrepancies in the findings. In addition all these studies were cross sectional and therefore liable to survival bias, which may further contribute to the variability of the results [18,19]. Longitudinal studies would overcome some of these limitations but existing evidence is limited to one study which has shown a lower frequency of new-onset microalbuminuria in people carriers of the PPARγ2 Ala variant [20]. This study was performed within the context of a randomized clinical trial designed to evaluate whether ACE inhibitors and calcium-channel blockers prevent new onset microalbuminuria in a selected group of diabetic people with hypertension, normoalbuminuria and no evidence of renal injury at baseline [20]. Data on renal function were not provided in this study, furthermore, due to selection criteria, it is not known to what extent the findings can be extrapolated to diabetic patients at large, including patients with more advanced renal damage. The present work expands current knowledge by evaluating the association of the Pro12Ala polymorphism of PPARγ2 with the progression of urinary albumin excretion and decay of glomerular filtration rate overtime in a clinic-based sample of patients with type 2 diabetes, representative of the diabetic patients seen in clinical practice.

Patients and methods

The study participants are 256 males and females with type 2 diabetes consecutively attending the outpatients Diabetes Clinic of the University Hospital for the screening of diabetes complications and with two complete examinations performed at least one year apart between January 1th 2002 and January 1th 2013. The longest available follow-up was analyzed. Exclusion criteria were age above 75 years, dialysis or renal transplantation, GFR < 30 ml/min/1.73 m², nephrotic syndrome (proteínuria > 3 g/die), urinary tract infection or congestive heart failure. At baseline and follow-up a full clinical evaluation was performed according to a standard protocol, all biochemical analyses were performed in the same laboratory undergoing regular external quality control. BMI was calculated as weight (Kg) /height (m²). Supine blood pressure was measured with standard protocol. Medication use and smoking habits were assessed by interview.

Glycated haemoglobin (HbA1c) was measured by HPLC. Urinary albumin and creatinine were measured on a morning spot urine sample by immunonephelometry and enzymatic colorimetric methods, respectively; the albumin/creatinine ratio was calculated; values <30 μg/mg, 30–299 μg/mg and ≥300 μg/mg in the absence of haematuria were defined as normo, micro or macroalbuminuria. GFR was estimated with the Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) Equation [21].

End points were UAER and estimated GFR. Progression of nephropathy was defined based on the occurrence of a composite end point including any of the followings : doubling of baseline UAER to at least 100 μg/mg; progression from normo to microalbuminuria or from micro to macroalbuminuria; decay of eGFR (i.e. 25% reduction from baseline, or anannualized eGFR decline >3 ml/min per year) [22,23].

Genomic DNA was isolated using Biorobot EZ1 Qiagen. By polymerase chain reaction (PCR) all samples were genotyped for the non-synonymous variation Pro12Ala (rs1801282) in the first exon of PPARγ2. The oligoprimers were tested by gradient PCR to optimize melting temperature. Genotyping was performed by an allele-specific amplification method using SYBR Green detection in a Realtime ABI PRISM 7000 apparatus (PE Applied Biosystem). In 5% of the samples genotyping was performed in duplicate and was fully concordant.

The study was approved by the university hospital ethics committee, informed consent was obtained from all participants.

Statistical analysis

Data is given as mean ± standard deviation (SD) for normally distributed variables and as median and Interquartile range (IQR) for variables showing substantial asymmetry. Accordingly, groups were compared by unpaired or paired Student's t-test, or by the equivalent non parametric procedures (Mann–Whitney and Wilcoxon matched pairs). Proportions were compared by Chi-square test. The Chi-square goodness-of-fit test was used to assess deviation from Hardy-Weinberg equilibrium of the genotypic frequency. The estimated proportions of subjects with a progression of nephropathy, as above defined, were derived with the use of the Kaplan-Meier product limit method and compared between groups by the Log-rank test. The Cox regression analysis was performed to explore the relationship between progression of nephropathy and Pro12Ala polymorphism after adjusting for potential confounding factors (i.e. age, diabetes duration, glucose control estimated by HbA1c, baseline UAER and eGFR, blood pressure and blockers of the renin angiotensin system. Results of the Cox regression model are reported as Hazard ratio (HR) with 95% Confidence Intervals (95% CI). All tests are two sided and p-value less than 0.05 was deemed as significant. The analyses were conducted using SPSS for Windows 16.0.

Results

The genotype distribution was in Hardy Weinberg equilibrium, 212 participants (82.8%) were Pro/Pro homozygotes, 44 (17.2%) Pro/Ala heterozygotes, no homozygotes
for the Ala variant were found. The characteristics of the study participants were similar in the two genotype groups. Age at onset of diabetes was 52.1 ± 9.6 and 53.6 ± 7.4 respectively in carriers or non-carriers of the ala allele. Attained age, BMI, gender distribution, diabetes duration, glycated haemoglobin, blood pressure; UAER, eGFR and the proportion of people with micro/macroalbuminuria or GFR < 60 ml/min/1.73 m², were comparable in the two genotype groups as was the proportion of current smokers, the proportion of people with retinopathy and the proportion of patients on antihypertensive medications (Table 1). As for antidiabetic treatment the proportion of people treated with diet, oral agents or insulin was similar in the two genotype groups. No one was treated with glitazones. The median follow-up was 5 years (IQR 3–7), similar in the two genotype groups. During the study period UAER remained stable in the Ala carriers [15.9 (IQR 9.4–26.3) versus 18.9 (IQR 11.9–30.7) µg/mg], whereas a significant increase was observed in people with the ProPro genotype [17.0 (IQR 11.3–37.9 µg/mg) versus 24.5 (IQR 13.8–49.9) µg/mg], p = 0.006 (Table 2). The estimated GFR remained unchanged in Ala carriers (85.3 ± 12 vs 85.2 ± 13 ml/min/1.73 m², p = ns) and declined slightly, but significantly, in the Pro/Pro group (82.8 ± 14.5 vs 80.3 ± 17.3 ml/min/1.73 m², p = 0.02) (Table 2). On average glucose control and blood pressure remained stable overtime in both genotype groups (Table 2). The proportion of patients with progression of nephropathy was significantly lower in patients carriers of the Ala polymorphism (11.4% vs 35.8%; p = 0.002, log rank test). The Cox regression analysis, performed with progression of nephropathy as the outcome variable and genotype, baseline age, UAER, eGFR, glycated haemoglobin, diabetes duration and blood pressure as predictor variables, confirmed a significant association of the Pro12Ala polymorphism with a lower risk of progression of nephropathy independent of established risk factors (HR = 0.32; 95% CI; 0.13–0.81 for 12Ala carriers vs non-carriers). A different model which included blockers of the renin angiotensin system instead of blood pressure provided similar results (HR = 0.30; 95% CI; 0.12–0.80). The Kaplan–Meier curve for progression of nephropathy in the two genotype groups is given in Figure 1.

**Table 1 Characteristics of the study population according to the Pro12Ala genotype**

|                          | Pro/Pro (N = 212) | ProAla (N = 44) |
|--------------------------|-------------------|-----------------|
| Males (%)                | 119 (56.1)        | 23 (52.3)       |
| Age (years)              | 60.9 ± 4.1        | 60.3 ± 5.7      |
| BMI (Kg/m²)              | 29.4 ± 4.0        | 29.6 ± 4.5      |
| Hb1Ac (%)                | 7.0 ± 1.5         | 6.9 ± 0.9       |
| Systolic BP (mmHg)       | 135.3 ± 18.6      | 133.0 ± 27.6    |
| Diastolic BP (mmHg)      | 78.4 ± 8.3        | 78.7 ± 15.9     |
| Diabetes duration (years)| 7.4 ± 6.3         | 8.2 ± 7.3       |
| Smokers (%)              | 49 (23.1)         | 11 (25)         |
| With Retinopathy (%)     | 49 (23.1)         | 12 (27.3)       |
| Treated with diet (%)    | 20 (9.6)          | 5 (11.9)        |
| Treated with oral agents (%) | 138 (66)     | 29 (69.1)       |
| Treated with insulin (%) | 51 (24.4)         | 8 (19)          |
| Treated with ACE or ARB (%) | 155 (73.1)       | 29 (65.9)       |
| Treated with Statins (%) | 131 (61.8)        | 21 (47.7)       |
| Microalbuminuria (%)     | 62 (29.2)         | 10 (22.7)       |
| Macroalbuminuria (%)     | 8 (3.8)           | 2 (4.5)         |
| GFR < 60 ml/min/1.73 m²  | 14 (6.7)          | 3 (7)           |

BP: Blood pressure UAER: Urinary albumin excretion rate; GFR: glomerular filtration rate.

**Discussion**

The study conducted in a representative sample of patients with type 2 diabetes, shows that the Pro12Ala polymorphism of PPARγ2 is associated with a significantly lower progression of UAER, a significantly lower decay of GFR, significantly less overall renal damage, as indicated by the lower incidence of a combined end point of clinically relevant progression of albuminuria and loss of renal function – as compared with carriers of the wild-type Pro/Pro genotype. To our knowledge this is the first study reporting on renal function overtime in relation to the Pro12Ala polymorphism of PPARγ2. Major risk factors for the progression of diabetic nephropathy such as diabetes duration, male sex and smoking habits were comparable in the two genotype groups, as well as age, baseline blood pressure, glucose control (HbA1c), UAER and eGFR, thus ruling out a confounding effect of these variables.

A lower progression of albumin excretion rate in carriers of the Ala allele is in line with the results of most, though not all, cross sectional studies, and recent meta-analyses reporting a lower prevalence of renal damage defined as increased UAER in carriers of the Ala allele [9-17] and is also coherent with results of the BENEDICT trial showing that in hypertensive diabetic patients with no evidence of renal injury at baseline, the Ala allele protects from new-onset microalbuminuria [20]. The present study expands current knowledge by providing data on progression to macroalbuminuria and decay of GFR over time which represent markers of more advanced stages of diabetic nephropathy. In addition the representativity of the study population makes the finding generalizable to the diabetic population at large.

To explore the mechanisms of the protection conferred by the Pro12Ala polymorphism of PPARγ2 is beyond the aims of the study and we can only speculate. Although PPARγ2 is generally perceived as a renoprotective factor in type 2 diabetes, how PPARγ2 exerts its favourable effects remains unclear. Both systemic and organ-specific
renoprotective effects of PPAR γ have been identified. At the systemic level PPARγ activation induces complex metabolic effects including improved insulin sensitivity, reduction of plasma glucose and blood pressure increased plasma adiponectin and reduced levels of circulating non-esterified fatty acids (NEFA) and insulin-desensitizing cytokines [24].

Prior studies have suggested that carriers of the 12 Ala allele show significantly improved insulin sensitivity and protection from diabetes as compared with wild type Pro/Pro homozygotes [3,5]. In addition the Ala 12 variant has been associated with an increased resistance to oxidative stress resulting from overproduction of reactive oxygen species under hyperglycemic conditions [4]. Both insulin resistance and oxidative stress have been suggested as determinants of the development and progression of diabetic nephropathy.

Based on these evidence, one likely, and conceivably causal, mechanism through which the the alanine variant of PPARγ2 may exert renal protective effects is via reduction of insulin resistance and oxidative stress.

Furthermore multiple renal cell lines (glomerular mesangial cells, podocytes, tubular epithelium, microvasculature) have endogenous PPARγ expression and there is evidence that activation of PPARγ expressed in the kidney itself may provide additional benefits by reducing mesangial

![Figure 1](image_url)
extracellular matrix production, maintaining podocyte number and function and limiting interstitial infiltration of monocytes/macrophages [25]. The hypothesis that the renoprotective properties of PPARy may be partly independent of metabolic effects is further supported by studies showing that the PPARy agonists thiazolidinediones attenuate progression of renal damage in diabetic nephropathy as well as in nepropathies not associated with metabolic abnormalities, including toxic and immune mediated renal injury [26-28]. Whether the Ala variant impacts on the expression and activity of PPAR γ at the renal level is unexplored and it is worth investigating.

In conclusion results of this study show a differential susceptibility to progression of diabetic nephropathy and loss of renal function in carriers or non carriers of the Pro12Ala polymorphism of PPAR γ2. These results are coherent with current knowledge on the role of PPARγ on the pathophysiology of diabetic nephropathy and lend further support to a conceivably causal association of the Pro12 Ala polymorphism with protection from diabetic nephropathy.

For better interpreting the results, some study limitations should be acknowledged. Firstly the small sample size and the definition of albuminuria based on a single measurement limited the ability to draw more solid conclusions, both conditions, however, are likely to bias the findings towards null, rather than towards positive. Secondly, due the observational design the study is hypothesis generating rather than conclusive. Nonetheless this is the first report on protection from worsening of renal function overtime in carriers of the Pro12Ala polymorphism of PPAR γ2, in addition the selection of a study sample representative of the diabetic patients routinely seen in clinical practice makes the results generalizable to the diabetic population at large.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
E. L designed the study, researched data and wrote the manuscript. AM researched data and reviewed the manuscript. SC researched data. MP researched data. S.C reviewed/edited manuscript. OV contributed to the study design, data analysis and, preparation of the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This work was supported in part by funds from the Italian Ministry of University, Research and Technology (MURST project 40, 2001/06573/2004).

Author details
1 Department of Clinical Medicine and Surgery, University of Naples Federico II, Via S Pansini 5, Naples 80131, Italy. 2 Department of Cellular and Molecular Biology and Pathology A. Califano DBPCM, University of Naples Federico II, Via S Pansini 5, Naples 80131, Italy. 3 IEO CNR, Via S Pansini 5, Naples 80131, Italy. 4 Department of Public Health, University of Naples Federico II, Via S Pansini 5, Naples 80131, Italy.

Received: 9 October 2014 Accepted: 27 February 2015
Published online: 12 March 2015

References
1. Sequestris ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1998;339:1161–5.
2. Rizvi S, Raza ST, Mahdi F. Association of genetic variants with diabetic nephropathy. World J Diabetes. 2014;5(5):809–16.
3. Deedh SS, Fajas L., Nemoto M, Phlhajmaki J, Mykkänen L, Kuskisto J, et al. A Pro12Ala substitution in PPARGamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20:284–7.
4. Liu W, Cao J, Li J, He W. Adipose tissue-specific PPARgamma deficiency increases resistance to oxidative stress. Exp Gerontol. 2008;43(5):154–63.
5. Gouda MN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol. 2010;171(6):645–55.
6. Badal SS, Danesh FR. New insights into molecular mechanisms of diabetic kidney disease. Am J Kidney Dis. 2014;63(2 Suppl 2):S63–83.
7. Singh AK, Kari JA. Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens. 2013;22(2):198–203.
8. Sarafidis PA, Georgianos PI, Lasaridis AN. PPAR-γ agonism for cardiovascular and renal protection. Cardiovasc Ther. 2011;29(6):377–84.
9. Liu L, Zheng T, Wang F, Wang N, Song Y, Li M, et al. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care. 2010;33(144–9).
10. Lapice E, Pinelli M, Riccardi G, Vaccaro O. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients: comment on the study by Liu et al. Diabetes Care. 2010;33:e114.
11. Erdogan M, Karadeniz M, Ergolu Z, Tescanik B, Selvi N, Yilmaz C. The relationship of the peroxisome proliferator-activated receptor gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Res Clin Pract. 2007;78:335–9.
12. Pollex RL, Mamakeesick M, Zinnman B, Harris SB, Hegele RA, Hanley AJ. Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications. 2007;21:166–71.
13. Caramori ML, Canani LH, Costa LA, Gross JLI. The human peroxisome proliferatoractivated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes. 2003;52:3010–3.
14. Herrmann SM, Ngeling J, Wang JG, Stansend JI, Brand E. Berlin Diabetes Mellitus (BeDiaM) Study. Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: the Berlin diabetes mellitus (BeDiaM) study. Diabetes. 2002;51:2653–7.
15. De Cosmo S, Prudente S, Lamacchia O, Lapice E, Morini E, Di Paola R, et al. PPAR (gamma) 2 P12Ala polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case–control studies. Nephrol Dial Transplant. 2011;26:4011–6.
16. Zhang H, Zhu S, Chen J, Tang Y, Hu H, Mohan V, et al. Peroxisome proliferator–activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care. 2012;35:1388–93.
17. Jonal A, Tannow L, Lajer M, Ek H, Hansen T, Pedersen O, et al. The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy. Mol Genet Metab. 2008;94(3):347–51.
18. Lapice E, Cocozza S, Riccardi G, Vaccaro O. Comment on: Zhang et al. Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care. 2013;36:1181-8.
19. Williams P, Pendyala L, Superko R. Survival bias and drug interaction can attenuate cross sectional case–control comparisons of genes with health outcomes: an example of the kinesin-like protein 6 (KIF6) Trp719Arg polymorphism and coronary heart disease. BMC Med Genet. 2011;12:42.
20. De Cosmo S, Motterlini N, Prudente S, Pellegrini F, Trevisan R, Bosi A, et al. BENEDICT Study Group. Impact of the PPARG2 Pro12Ala polymorphism and
ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. Diabetes. 2009;58:2020–9.

21. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.

22. August P, Hardison RM, Hage FG, Marroquin OC, McGill JB, Rosenberg Y, et al. Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study. Clin J Am Soc Nephrol. 2014;9(1):64–71.

23. Stevens LA, Greene T, Levey AS. Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol. 2006;1:874–84.

24. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19:557–66.

25. Yang J, Zhou Y, Guan Y. PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases. Curr Opin Nephrol Hypertens. 2012;21(1):97–105.

26. Chung BH, Lim SW, Ahn KO, Sugawara A, Ito S, Choi BS, et al. Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases. Nephrology. 2005;10 (supplement 2):S40–3.

27. Jia Z, Sun Y, Yang G, Zhang A, Huang S, Heiney KM, et al. New Insights into the PPAR γ agonists for the treatment of diabetic nephropathy. PPAR Res. 2014;2014:818530.

28. Ochodnicky P, Mesarosova L, Cermekova H, Klimas J, Kronek P, Gotes M, et al. Pioglitazone, a PPARγ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat. Eur J Pharmacol. 2014;730:51–60.